Drugs / TQB3201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07172126 | Sep 2025 → Apr 2027 expected | prostate carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
2025年，中国生物制药共有3款PROTAC新药首次获得临床批准。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172126 ↗ |
| Action | Inhibit | “target the degradation of wild-type AR” NCT07172126 ↗ |
| Modality | Other / unclassified | “targeted protein chimera (PROTAC) drug” NCT07172126 ↗ |
| Route | Oral | “orally administered” NCT07172126 ↗ |
| Target | AR | “binds to AR” NCT07172126 ↗ |